|
1
|
Ritter J and Bielack SS: Osteosarcoma. Ann
Oncol. 21 Suppl 7:vii320–vii325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Terezhalmy GT, Riley CK and Moore WS:
Osteosarcoma. Quintessence Int. 31:592–593. 2000.PubMed/NCBI
|
|
3
|
Moore DD and Luu HH: Osteosarcoma. Cancer
Treat Res. 162:65–92. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Meyers PA, Heller G, Healey JH, Huvos A,
Applewhite A, Sun M and LaQuaglia M: Osteogenic sarcoma with
clinically detectable metastasis at initial presentation. J Clin
Oncol. 11:449–453. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kager L, Zoubek A, Pötschger U, Kastner U,
Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M,
Winkelmann W, et al Cooperative German-Austrian-Swiss Osteosarcoma
Study Group, : Primary metastatic osteosarcoma: Presentation and
outcome of patients treated on neoadjuvant Cooperative Osteosarcoma
Study Group protocols. J Clin Oncol. 21:2011–2018. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rasalkar DD, Chu WC, Lee V, Paunipagar BK,
Cheng FW and Li CK: Pulmonary metastases in children with
osteosarcoma: Characteristics and impact on patient survival.
Pediatr Radiol. 41:227–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Meyers PA, Schwartz CL, Krailo M,
Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W,
Gebhardt M, Goorin AM, et al: Osteosarcoma: A randomized,
prospective trial of the addition of ifosfamide and/or muramyl
tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J
Clin Oncol. 23:2004–2011. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Meyers PA, Schwartz CL, Krailo MD, Healey
JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM,
Harris M, et al Children's Oncology Group, : Osteosarcoma: The
addition of muramyl tripeptide to chemotherapy improves overall
survival - a report from the Children's Oncology Group. J Clin
Oncol. 26:633–638. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang H, Lin JJ, Su ZZ, Goldstein NI and
Fisher PB: Subtraction hybridization identifies a novel melanoma
differentiation associated gene, mda-7, modulated during human
melanoma differentiation, growth and progression. Oncogene.
11:2477–2486. 1995.PubMed/NCBI
|
|
10
|
Caudell EG, Mumm JB, Poindexter N,
Ekmekcioglu S, Mhashilkar AM, Yang XH, Retter MW, Hill P, Chada S
and Grimm EA: The protein product of the tumor suppressor gene,
melanoma differentiation-associated gene 7, exhibits
immunostimulatory activity and is designated IL-24. J Immunol.
168:6041–6046. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sauane M, Gopalkrishnan RV, Sarkar D, Su
ZZ, Lebedeva IV, Dent P, Pestka S and Fisher PB: MDA-7/IL-24: Novel
cancer growth suppressing and apoptosis inducing cytokine. Cytokine
Growth Factor Rev. 14:35–51. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Whitaker EL, Filippov VA and
Duerksen-Hughes PJ: Interleukin 24: Mechanisms and therapeutic
potential of an anti-cancer gene. Cytokine Growth Factor Rev.
23:323–331. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Su ZZ, Lebedeva IV, Sarkar D, Emdad L,
Gupta P, Kitada S, Dent P, Reed JC and Fisher PB: Ionizing
radiation enhances therapeutic activity of mda-7/IL-24: Overcoming
radiation- and mda-7/IL-24-resistance in prostate cancer cells
overexpressing the antiapoptotic proteins bcl-xL or bcl-2.
Oncogene. 25:2339–2348. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dent P, Yacoub A, Hamed HA, Park MA, Dash
R, Bhutia SK, Sarkar D, Wang XY, Gupta P, Emdad L, et al: The
development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol Ther.
128:375–384. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhuo B, Wang R, Zhang H, Qin H, Yin Y and
Shi Y: Interleukin-24 inhibits cell migration and invasion in the
neuroblastoma cell line SH-SY5Y. Oncol Rep. 30:2749–2754.
2013.PubMed/NCBI
|
|
16
|
Zhuo B, Wang R, Yin Y, Zhang H, Ma T, Liu
F, Cao H and Shi Y: Adenovirus arming human IL-24 inhibits
neuroblastoma cell proliferation in vitro and xenograft tumor
growth in vivo. Tumour Biol. 34:2419–2426. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ramesh R, Ito I, Gopalan B, Saito Y,
Mhashilkar AM and Chada S: Ectopic production of MDA-7/IL-24
inhibits invasion and migration of human lung cancer cells. Mol
Ther. 9:510–518. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shi H, Wei LL, Yuan CF, Yang JX, Yi FP, Ma
YP and Song FZ: Melanoma differentiation-associated
gene-7/interleukin 24 inhibits invasion and migration of human
cervical cancer cells in vitro. Saudi Med J. 28:1671–1675.
2007.PubMed/NCBI
|
|
19
|
Xiao CW, Xue XB, Zhang H, Gao W, Yu Y,
Chen K, Zheng JW and Wang CJ: Oncolytic adenovirus-mediated
MDA-7/IL-24 overexpression enhances antitumor activity in
hepatocellular carcinoma cell lines. Hepatobiliary Pancreat Dis
Int. 9:615–621. 2010.PubMed/NCBI
|
|
20
|
Fisher PB, Sarkar D, Lebedeva IV, Emdad L,
Gupta P, Sauane M, Su ZZ, Grant S, Dent P, Curiel DT, et al:
Melanoma differentiation associated gene-7/interleukin-24
(mda-7/IL-24): Novel gene therapeutic for metastatic melanoma.
Toxicol Appl Pharmacol. 224:300–307. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bjørnland K, Flatmark K, Pettersen S,
Aaasen AO, Fodstad O and Maelandsmo GM: Matrix metalloproteinases
participate in osteosarcoma invasion. J Surg Res. 127:151–156.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamaguchi H, Wyckoff J and Condeelis J:
Cell migration in tumors. Curr Opin Cell Biol. 17:559–564. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Carragher NO and Frame MC: Focal adhesion
and actin dynamics: A place where kinases and proteases meet to
promote invasion. Trends Cell Biol. 14:241–249. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pickup MW, Mouw JK and Weaver VM: The
extracellular matrix modulates the hallmarks of cancer. EMBO Rep.
15:1243–1253. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wolf K, Wu YI, Liu Y, Geiger J, Tam E,
Overall C, Stack MS and Friedl P: Multi-step pericellular
proteolysis controls the transition from individual to collective
cancer cell invasion. Nat Cell Biol. 9:893–904. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wolf K and Friedl P: Extracellular matrix
determinants of proteolytic and non-proteolytic cell migration.
Trends Cell Biol. 21:736–744. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
McCawley LJ and Matrisian LM: Matrix
metalloproteinases: Multifunctional contributors to tumor
progression. Mol Med Today. 6:149–156. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Khanna C, Wan X, Bose S, Cassaday R, Olomu
O, Mendoza A, Yeung C, Gorlick R, Hewitt SM and Helman LJ: The
membrane-cytoskeleton linker ezrin is necessary for osteosarcoma
metastasis. Nat Med. 10:182–186. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang CY, Lee CY, Chen MY, Yang WH, Chen
YH, Chang CH, Hsu HC, Fong YC and Tang CH: Stromal cell-derived
factor-1/CXCR4 enhanced motility of human osteosarcoma cells
involves MEK1/2, ERK and NF-kappaB-dependent pathways. J Cell
Physiol. 221:204–212. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Iiizumi M, Bandyopadhyay S, Pai SK, Watabe
M, Hirota S, Hosobe S, Tsukada T, Miura K, Saito K, Furuta E, et
al: RhoC promotes metastasis via activation of the Pyk2 pathway in
prostate cancer. Cancer Res. 68:7613–7620. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang Q, Lan F, Wang X, Yu Y, Ouyang X,
Zheng F, Han J, Lin Y, Xie Y, Xie F, et al: IL-1β-induced
activation of p38 promotes metastasis in gastric adenocarcinoma via
upregulation of AP-1/c-fos, MMP2 and MMP9. Mol Cancer. 13:182014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Moon SK, Kim HM, Lee YC and Kim CH:
Disialoganglioside (GD3) synthase gene expression suppresses
vascular smooth muscle cell responses via the inhibition of ERK1/2
phosphorylation, cell cycle progression, and matrix
metalloproteinase-9 expression. J Biol Chem. 279:33063–33070. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gao X, Balan V, Tai G and Raz A:
Galectin-3 induces cell migration via a calcium-sensitive
MAPK/ERK1/2 pathway. Oncotarget. 5:2077–2084. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hsieh YS, Chu SC, Yang SF, Chen PN, Liu YC
and Lu KH: Silibinin suppresses human osteosarcoma MG-63 cell
invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of
MMP-2. Carcinogenesis. 28:977–987. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fromigué O, Hamidouche Z and Marie PJ:
Statin-induced inhibition of 3-hydroxy-3-methyl glutaryl coenzyme a
reductase sensitizes human osteosarcoma cells to anticancer drugs.
J Pharmacol Exp Ther. 325:595–600. 2008. View Article : Google Scholar : PubMed/NCBI
|
